TargetMol

BBIQ

Product Code:
 
TAR-T14513
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T14513-5mg5mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14513-1mL1 mL * 10 mM (in DMSO)£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14513-10mg10mg£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14513-25mg25mg£143.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14513-50mg50mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BBIQ is a powerful vaccine adjuvant that enhances innate immune responses and it is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of ?59.1?nM for human TLR7.
CAS:
1229024-57-0
Formula:
C21H22N4
Molecular Weight:
330.43
Pathway:
Immunology/Inflammation
Purity:
0.9802
SMILES:
N1=C(N)C=2N=C(N(C2C=3C=CC=CC13)CC=4C=CC=CC4)CCCC
Target:
TLR

References

1. Saroa R, et al. Efficacy of TLR7 agonistic imidazoquinoline as immunochemotherapeutic agent against P. Berghei ANKA infected rodent host. Bioorg Med Chem Lett. 2019 May 1;29(9):1099-1105. 2. Kaushik D, et al. BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant. Hum Vaccin Immunother. 2020 Apr 16:1-8.